Chief Business Officer and member of the Executive Committee of Cellectis. Prior to this position, he was Vice President, Corporate Development at Cellectis, responsible for program management, strategy and business development. Cellectis is a clinical-stage biopharmaceutical company developing gene-edited allogeneic CAR-T immunotherapies in oncology. Arthur began his career at the European Commission’s Directorate-General for Competition, controlling global pharmaceutical mergers such as the Novartis/GSK and Sanofi/Boehringer Ingelheim asset swaps, Pfizer’s acquisition of Hospira and Teva’s acquisition of Actavis Generics. He later became Head of the Hospital Financing unit at the French Ministry of Health, where he led a team responsible for the €80bn hospital budget. Arthur graduated from the École Normale Supérieure, Paris and Cambridge University, and holds a diploma in Immunotherapy from the Université Paris-Descartes. Arthur is also a member of the French Corps des Mines.
For a reasonably open world
